Related Experiment Videos
Hyporesponsiveness to anemia therapy--what are we doing wrong?
1Department of Renal Medicine, King's College Hospital, London, UK. icm-kru@globalnet.co.uk
Summary
Most anemia therapy patients respond to erythropoietin, but 5%-10% show hyporesponsiveness. Investigating this involves checking iron levels, inflammation, and dialysis adequacy, guiding further treatment for better hemoglobin levels.
Area of Science:
- Nephrology
- Hematology
- Internal Medicine
Background:
- Anemia therapy, primarily using erythropoietin, benefits most patients.
- A subset of 5%-10% of patients exhibit hyporesponsiveness to erythropoietin therapy.
- Hyporesponsiveness is often defined as failing to reach 10-11 g/dL hemoglobin despite >200 U/kg/week erythropoietin.
Purpose of the Study:
- To outline the diagnostic approach for patients with hyporesponsiveness to anemia therapy.
- To identify common and less common causes of poor response to erythropoietin.
- To guide clinical management strategies for optimizing anemia treatment.
Main Methods:
- Systematic investigation starting with compliance and iron deficiency screening.
- Assessment for infection, inflammation (e.g., C-reactive protein), and underdialysis.
- Consideration of reticulocyte count, bone marrow biopsy, and dose adjustments.
Main Results:
- Iron deficiency, infection/inflammation, and underdialysis are primary causes of hyporesponsiveness.
- Reticulocyte counts can indicate hemolysis or blood loss.
- Bone marrow biopsy may be necessary for diagnosing primary disorders.
Conclusions:
- Correctable causes like iron deficiency and underdialysis should be addressed first.
- Some patients may require significantly increased erythropoietin doses.
- Uncorrectable causes include primary bone marrow disorders and hemoglobinopathies, limiting treatment options.